PMID- 31237044 OWN - NLM STAT- MEDLINE DCOM- 20200128 LR - 20221207 IS - 1098-2744 (Electronic) IS - 0899-1987 (Linking) VI - 58 IP - 10 DP - 2019 Oct TI - Aberrant ERG expression associates with downregulation of miR-4638-5p and selected genomic alterations in a subset of diffuse large B-cell lymphoma. PG - 1846-1854 LID - 10.1002/mc.23074 [doi] AB - ERG (avian v-ets erythroblastosis virus E26 oncogene homolog), an oncoprotein in prostate carcinoma and Ewing's sarcoma is associated with poor prognosis in patients with acute myeloid leukemia and T lymphoblastic leukemia. However little is known about ERG in lymphoma. Here we studied ERG in diffuse large B-cell lymphoma (DLBCL) by immunohistochemistry, fluorescence in situ hybridization (FISH), genome-wide microRNA (miRNA) expression profiling, real-time reverse-transcriptase polymerase chain reaction (RT-PCR) and whole exome sequencing (WES). Approximately 30% of de novo DLBCLs (37 of 118) expressed ERG (ERG+). ERG expression showed no significant correlation with DLBCL cell-of-origin classification, patient's age, sex, nodal, or extranodal disease status, tumor expression of p53 or p63. There was no ERG rearrangement in 10 randomly selected ERG+ DLBCLs by FISH. Forty-three miRNAs showed significant differential expression between ERG+ and ERG- DLBCLs. Downregulation of miR-4638-5p was confirmed by real-time RT-PCR. WES not only confirmed known gene mutations in DLBCLs but also revealed multiple novel gene mutations in POLA1, E2F1, PSMD8, AXIN1, GAB2, and GNB2L1, which occur more frequently in ERG+ DLBCLs. In conclusion, our studies demonstrated aberrant ERG expression in a subset of DLBCL, which is associated with downregulation of miR-4638-5p. In comparison with ERG-negative DLBCL, ERG+ DLBCL more likely harbors mutations in genes important in cell cycle control, B-cell receptor-mediated signaling and degradation of beta-catenin. Further clinicopathological correlation and functional studies of ERG-related miRNAs and pathways may provide new insight into the pathogenesis of DLBCL and reveal novel targets for better management of patients with DLBCL. CI - (c) 2019 Wiley Periodicals, Inc. FAU - Zhang, Shanxiang AU - Zhang S AUID- ORCID: 0000-0001-8525-7021 AD - Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Wang, Lin AU - Wang L AD - Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana. FAU - Cheng, Liang AU - Cheng L AD - Department of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20190624 PL - United States TA - Mol Carcinog JT - Molecular carcinogenesis JID - 8811105 RN - 0 (ERG protein, human) RN - 0 (MIRN4638 microRNA, human) RN - 0 (MicroRNAs) RN - 0 (Neoplasm Proteins) RN - 0 (Transcriptional Regulator ERG) SB - IM MH - Disease-Free Survival MH - Female MH - Gene Expression Regulation, Neoplastic MH - Genomics MH - Humans MH - In Situ Hybridization, Fluorescence MH - Lymphoma, Large B-Cell, Diffuse/*genetics/pathology MH - Male MH - MicroRNAs/*genetics MH - Middle Aged MH - Neoplasm Proteins/genetics MH - Prognosis MH - Signal Transduction/genetics MH - Transcriptional Regulator ERG/genetics MH - Exome Sequencing OTO - NOTNLM OT - ERG OT - diffuse large B-cell lymphoma OT - genomic pathway OT - microRNA OT - whole exome sequencing EDAT- 2019/06/27 06:00 MHDA- 2020/01/29 06:00 CRDT- 2019/06/26 06:00 PHST- 2019/03/27 00:00 [received] PHST- 2019/05/22 00:00 [revised] PHST- 2019/05/31 00:00 [accepted] PHST- 2019/06/27 06:00 [pubmed] PHST- 2020/01/29 06:00 [medline] PHST- 2019/06/26 06:00 [entrez] AID - 10.1002/mc.23074 [doi] PST - ppublish SO - Mol Carcinog. 2019 Oct;58(10):1846-1854. doi: 10.1002/mc.23074. Epub 2019 Jun 24.